Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7
Status:
RECRUITING
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of toripalimab plus actinomycin-D as fist-line treatment in patients with gestational trophoblastic neoplasia with FIGO score 7. The main questions it aims to answer are:
* Whether toripalimab plus actinomycin-D as fist-line treatment can achieve a high complete response rate.
* Whether an equally high cure rate can be achieved by multi-drug chemotherapy as second-line treatment in patients who have failed fist-line treatment with toripalimab plus actinomycin-D.
Participants will receive toripalimab plus actinomycin-D. Treatment will be continued until disease progression, unacceptable toxicity, or withdrawal of consent. Treatment will be completed after 4 consolidation cycles.
Phase:
PHASE2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Dalian Maternity and Child Care Hospital Gansu Provincial Maternal and Child Health Care Hospital Henan Cancer Hospital Obstetrics & Gynecology Hospital of Fudan University Shanghai Junshi Bioscience Co., Ltd. Shengjing Hospital Sichuan Cancer Hospital and Research Institute Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The First Affiliated Hospital of Xiamen University